Raymond James hires senior biotechnology research analyst

ST. PETERSBURG, Fla. – Raymond James has hired Martin Auster, M.D. as a senior equity research analyst and managing director covering biotechnology companies. Dr. Auster has more than 20 years of experience on the sell-side, buy-side and in the biotech industry, a broad background that combines both technical and financial knowledge to provide clients with deep industry expertise and unique insights.

“Marty is a highly regarded research analyst and biotech company executive whose diverse background and extensive experience will play a pivotal role as we continue to advance our biotech practice,” said Brian Alexander, senior managing director and director of Equity Research. “I look forward to partnering with him in setting the strategic direction of our biotech research practice.”

Dr. Auster joins Raymond James after most recently serving as CFO of Ventyx Biosciences, a public clinical-stage biopharma company. He most recently covered the biotech sector as a research analyst at Credit Suisse and gained further industry experience during roles at Ascendis Pharma A/S and United Therapeutics.

"Raymond James has made significant commitments toward building a strong and durable life sciences and biotechnology business,” said Dr. Auster. “I am excited to join the firm at this juncture and look forward to producing thoughtful, provocative research for the benefit of our clients."

About Raymond James Financial, Inc.

Raymond James Financial, Inc. (NYSE: RJF) is a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporations and municipalities. Total client assets are $1.56* trillion. Public since 1983, the firm is listed on the New York Stock Exchange under the symbol RJF. Additional information is available at www.raymondjames.com.

*As of 12/31/2024. Past performance is not an indication of future results. The information provided is for informational purposes only and is not a solicitation to buy or sell Raymond James Financial stock.